https://www.selleckchem.com/pr....oducts/ins018-055-is
€21,897 [10,600]; P0.001) due to higher bDMARD acquisition costs (€23,996 [4,818] vs. €16,427 [9,033]; P0.001), persistence reduced inpatient treatment costs (-€76, outpatient treatment costs (-€192), other drug costs (-€724), and sick leave costs (-€601). Although initiation of bDMARDs increased the total healthcare costs irrespective of persistence status, partial cost offsets were observed in the persistent patient population. Although initiation of bDMARDs increased the total healthcare costs irrespective of
Like
Comment
Share
